Loracarbef

Chemical compound
  • J01DC08 (WHO)
Pharmacokinetic dataProtein binding25%Identifiers
  • (6R,7S)-7-[[(2S)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
CAS Number
  • 76470-66-1 checkY
PubChem CID
  • 5284584
DrugBank
  • DB00447 checkY
ChemSpider
  • 4447634 checkY
UNII
  • W72I5ZT78Z
KEGG
  • D08143 checkY
ChEMBL
  • ChEMBL1013 ☒N
CompTox Dashboard (EPA)
  • DTXSID7023223 Edit this at Wikidata
Chemical and physical dataFormulaC16H16ClN3O4Molar mass349.77 g·mol−13D model (JSmol)
  • Interactive image
  • Cl\C3=C(/C(=O)O)N2C(=O)[C@@H](NC(=O)[C@@H](c1ccccc1)N)[C@H]2CC3.O
InChI
  • InChI=1S/C16H16ClN3O4.H2O/c17-9-6-7-10-12(15(22)20(10)13(9)16(23)24)19-14(21)11(18)8-4-2-1-3-5-8;/h1-5,10-12H,6-7,18H2,(H,19,21)(H,23,24);1H2/t10-,11-,12+;/m1./s1 checkY
  • Key:GPYKKBAAPVOCIW-HSASPSRMSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Loracarbef is an antibiotic.[1] It is a carbacephem, but it is sometimes grouped together with the second-generation cephalosporin antibiotics. Loracarbef is a synthetic "carba" analog of cefaclor, and is more stable.

History

Loracarbef received FDA approval in 1991 and it was marketed under the trade name Lorabid. Its use was discontinued in 2006.[citation needed]

Usage & indications

Loracarbef was used to treat infections of the lungs, maxillary sinuses, throat, skin, and urinary tract.[2]

Spectrum of activity

Loracarbef had broad spectrum effectiveness against both gram-negative and gram-positive bacteria, including those precipitating infections of the respiratory tract, sinuses, tonsils, skin, urinary tract, and kidneys. It was of specific use in those infections caused by E. coli,S. pyogenes,S. aureus, S. saprophyticus, S. pneumoniae, H. influenzae and M. catarrhalis. [3]

Side effects

Diarrhea is the most common adverse effect with loracarbef. Side effects are more frequently seen with children under the age of twelve.[citation needed]

References

  1. ^ Biedenbach DJ, Jones RN (February 1994). "Predictive accuracy of disk diffusion test for Proteus vulgaris and Providencia species against five newer orally administered cephalosporins, cefdinir, cefetamet, cefprozil, cefuroxime, and loracarbef". Journal of Clinical Microbiology. 32 (2): 559–62. doi:10.1128/JCM.32.2.559-562.1994. PMC 263078. PMID 8150976.
  2. ^ "Lorabid (Loracarbef): Uses, Dosage, Side Effects, Interactions, Warning". RxList. Retrieved 2020-06-15.
  3. ^ "Loracarbef". www.drugbank.ca. Retrieved 2020-06-15.

External links

  • RxList.com - Loracarbef
  • v
  • t
  • e
  • v
  • t
  • e
Beta-lactams
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Penicillins (Penams)
Narrow
spectrum
β-lactamase sensitive
(1st generation)
β-lactamase resistant
(2nd generation)
Extended
spectrum
Aminopenicillins (3rd generation)
Carboxypenicillins (4th generation)
Ureidopenicillins (4th generation)
Other
Carbapenems / Penems
Cephems
Cephalosporins
Cephamycins
Carbacephems
1st generation
2nd generation
3rd generation
4th generation
5th generation
Siderophore
Veterinary
Monobactams
β-lactamase inhibitors
Combinations
Polypeptides
Glycopeptides
Lipoglycopeptides
Lipopeptides
Polymyxins
Other
  • Inhibits PG elongation and crosslinking: Ramoplanin§
Intracellular
Other